Overview

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nacuity Pharmaceuticals, Inc.

Collaborator:

Foundation Fighting Blindness

Treatments:

Acetylcysteine